Physician profile
Tanya E Ray
NPI 1326421421
$841.99
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $211 · 2022: $198 · 2023: $369 · 2024: $64.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.26 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $224.89 | 2021-2023 | Slynd |
| Mayne Pharma Commercial LLC | $210.45 | 2021-2024 | |
| Abbvie INC. | $99.98 | 2021-2024 | |
| Evofem Biosciences, INC. | $86.63 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $43.81 | 2021 | |
| Agile Therapeutics, INC. | $39.97 | 2021-2023 | Twirla |
| Myovant Sciences INC. | $34.18 | 2021-2022 | |
| Pfizer INC. | $16.92 | 2022 | |
| Becton, Dickinson and Company | $16.68 | 2023 | Bd Onclarity |
| Shield Therapeutics INC | $16.07 | 2023 | Accrufer |
| Therapeuticsmd, INC. | $14.06 | 2021 | |
| Millicent US INC | $13.35 | 2024 | |
| Amag Pharmaceuticals, INC. | $12.87 | 2021 | |
| Abbott Laboratories | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanya Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.